Work

COVID-19 convalescent plasma in immunocompromised COVID-19 patients: more certainty and clarity are added to a complex evidence base

Year: 2025

Type: article

Abstract: In their article in EBioMedicine, Hoffman and colleagues report the results of a phase 3 multicenter trial, COVIC-19 (“Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19”), conducted in 10 European centres during the Omicron era. The trial enrolled immunocompromised outpatients with mild COVID-19 a median of four days from symptom onset and randomized them 1:1 to receive COVID-19 convalescent plasma (CCP) plus standard of care (SoC) or SoC alone in an open-label design.

Source: EBioMedicine

DOI: 10.1016/j.ebiom.2025.105654

Authors: Hyunah Yoon, Liise-anne Pirofski

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,780